Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE‐B trial 2 years after gene therapy

Robbin Itzler,Tyler W. Buckner,Frank W. G. Leebeek,Joel Miller,Michael Recht,Douglass Drelich,Paul E. Monahan,Steven W. Pipe
DOI: https://doi.org/10.1111/hae.14977
2024-03-12
Haemophilia
Abstract:Introduction For people with haemophilia B (PwHB), bleeding may occur despite prophylaxis, negatively affecting health‐related quality of life (HRQoL). The pivotal phase 3 HOPE‐B trial investigating the adeno‐associated virus gene transfer product, etranacogene dezaparvovec (EDZ), demonstrated sustained factor IX (FIX) activity and bleed protection in PwHB with baseline FIX levels ≤2%. Aim Assess how EDZ affects HRQoL in HOPE‐B trial participants. Methods HRQoL was evaluated using generic and disease‐specific patient reported outcomes (PROs) including the EQ‐5D‐5L and the Hem‐A‐QoL questionnaires. Mean domain and total scores were compared 6 months pre‐ and the first 2 years post‐EDZ administration using repeated measures linear mixed models. The percentage of participants with minimal clinically important improvements in HRQoL was also evaluated. Results Two years post‐EDZ, there were nominally significant increases in the least squares (LS) mean score for the EQ‐5D‐5L Index Value (.04; p = .0129), reflecting better HRQoL. Nominally significant decreases in the LS mean scores, reflecting better HRQoL, were also found for the Hem‐A‐QoL total score (−6.0; p
hematology
What problem does this paper attempt to address?